Immunome Inc (IMNM) Stock Price, Quote & News

Company Profile

Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It...

Industry: Biotechnology

Sector: Healthcare

Phone: 425 939 7410

Website: immunome.com

Address:

18702 North Creek Parkway, Suite 100, Bothell, United States

EingeLTrade Apr. 1 at 8:29 PM

Up from here❔🤔 $IMNM

0 · Reply

TrendEdgeLogan Mar. 31 at 5:21 PM

$GH $KYMR $IMNM $NAMS $SOPH OCS PVLA ZYM SRZN ^^ best of the best healthcare / biotech names right now

0 · Reply

TradeMechanics_ Mar. 31 at 2:24 PM

Insider signal just dropped on $IMNM CEO Clay B. Siegall stepped in and bought 25,450 shares on the open market, with a weighted average price of $19.67 (range: $19.63–$19.70). That’s not a small gesture—that’s conviction buying from the top. When leadership puts real capital to work at these levels, it often signals alignment with the company’s outlook. Insiders don’t chase headlines—they buy when they believe the current price undervalues the story. Is this a bottom signal or just confidence in execution ahead? Either way, it’s a datapoint worth watching closely.

0 · Reply

CEOBuysDisclosures Mar. 31 at 1:15 PM

$IMNM CEO purchased 25,450 shares at $19.67 for a total of $500,602. SIEGALL CLAY B now owns 690,704 shares. https://ceo-buys.com

0 · Reply

FilingTracker Mar. 31 at 11:13 AM

$IMNM $500K insider purchase by President and CEO: https://www.sec.gov/Archives/edgar/data/1167496/000116749626000003/xslF345X06/form4-03312026_110335.xml

0 · Reply

RadioIsotope25 Mar. 28 at 1:42 PM

Radiopharm Theranostics (ASX: RAD) Investor Webinar -- RAD 101 Phase 2b second interim data - Zoom $RADX $ARTL $DRTS $IMNM https://us02web.zoom.us/rec/play/jHo4QT2d91u1IuLLzNdkfW7O01zHB8XV7X4-USlV2y-4TPZFkHt4U3BZJIlXY9cRVVMI-WgS-3Ji3Rtg.dh4n_6T8eCGOud-B

3 · Reply

RadioIsotope25 Mar. 23 at 11:08 PM

$RADX Meets 90% news just broke on RAD101 $IMNM $AKTS

0 · Reply

Jeff9905 Mar. 19 at 5:41 PM

$IMNM so they have tripled their employee count in the last 18 months. Why can't they get anything to the finish line?

0 · Reply

RadioIsotope25 Mar. 15 at 3:23 PM

Radiopharmaceutical buyouts and Market Caps $RADX $IMNM $PYXS $CELC

1 · Reply

RadioIsotope25 Mar. 13 at 4:43 PM

Diamond in the Rough $RADX $PYXS $IMNM $SMMT $AKTS

0 · Reply

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 11, 2026, 12:51 AM EDT - 25 days ago

Immunome: Upcoming NDA, Valuation, And Investment Case

Mar 3, 2026, 4:02 PM EST - 4 weeks ago

Immunome Reports Full Year 2025 Financial Results and Provides Business Update

Feb 23, 2026, 8:00 AM EST - 5 weeks ago

Immunome to Present at Upcoming Investor Conferences

Feb 4, 2026, 8:00 AM EST - 2 months ago

Immunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Jan 6, 2026, 8:00 AM EST - 3 months ago

Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 17, 2025, 2:44 PM EST - 3 months ago

Immunome: Maintaining "Strong Buy" On Successful RINGSIDE Trial With Varegacestat

Dec 16, 2025, 8:16 PM EST - 3 months ago

Immunome Announces Pricing of Public Offering of Common Stock

Dec 15, 2025, 4:01 PM EST - 3 months ago

Immunome Announces Proposed Public Offering of Common Stock

Dec 15, 2025, 7:16 AM EST - 3 months ago

Immunome's experimental drug meets main goal in late-stage study

Dec 15, 2025, 7:00 AM EST - 3 months ago

Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

Dec 14, 2025, 4:00 PM EST - 3 months ago

Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors

Nov 6, 2025, 4:05 PM EST - 5 months ago

Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 31, 2025, 11:51 AM EDT - 5 months ago

Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation Conference

Oct 23, 2025, 12:00 PM EDT - 5 months ago

Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance

Sep 18, 2025, 8:00 AM EDT - 7 months ago

Infinimmune Announces Research Collaboration with Immunome

Sep 3, 2025, 8:00 AM EDT - 7 months ago

Immunome to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 11, 2025, 10:31 PM EDT - 8 months ago

Immunome: SpringWorks Buyout Informs The Potential Upside Here

Aug 6, 2025, 4:05 PM EDT - 8 months ago

Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 4:05 PM EDT - 11 months ago

Immunome Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 17, 2025, 6:06 AM EDT - 1 year ago

Immunome: Transformed Pipeline Offers Multiple Catalysts

Apr 4, 2025, 8:00 AM EDT - 1 year ago

Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 19, 2025, 4:05 PM EDT - 1 year ago

Immunome Reports Full Year 2024 Financial Results and Provides Business Update

Mar 10, 2025, 7:41 AM EDT - 1 year ago

Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC

Feb 25, 2025, 8:00 AM EST - 1 year ago

Immunome to Present at Upcoming March Conferences

Jan 31, 2025, 4:01 PM EST - 1 year ago

Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 30, 2025, 10:27 AM EST - 1 year ago

Immunome Can Take The Fight To Competitors With Varegacestat

Jan 29, 2025, 11:11 PM EST - 1 year ago

Immunome Announces Pricing of Upsized Public Offering of Common Stock

Jan 13, 2025, 8:00 AM EST - 1 year ago

Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 27, 2024, 8:00 AM EST - 1 year ago

Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference

Nov 13, 2024, 4:05 PM EST - 1 year ago

Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 5, 2024, 8:00 AM EST - 1 year ago

Immunome to Present at Guggenheim's Inaugural Healthcare Innovation Conference

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021

Oct 18, 2024, 8:00 AM EDT - 1 year ago

Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium

Oct 8, 2024, 8:05 AM EDT - 1 year ago

Immunome Appoints Roee Shahar as Executive Vice President, Commercial

Sep 13, 2024, 7:00 AM EDT - 1 year ago

Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

Aug 29, 2024, 8:00 AM EDT - 1 year ago

Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 25, 2024, 8:00 AM EDT - 1 year ago

Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities

Jun 27, 2024, 2:14 PM EDT - 1 year ago

Immunome: AL102 And Other Established Protein Targets Could Drive Value

Jun 27, 2024, 8:00 AM EDT - 1 year ago

Immunome Appoints Phil Tsai as Chief Technical Officer

May 20, 2024, 8:00 AM EDT - 2 years ago

Immunome Announces Completion of Purchase of Assets from Atreca

May 17, 2024, 8:00 AM EDT - 2 years ago

Immunome Announces Promotion of Max Rosett to Chief Financial Officer

May 14, 2024, 8:00 AM EDT - 2 years ago

Immunome Reports First Quarter 2024 Financial Results and Provides Business Update

May 8, 2024, 8:00 AM EDT - 2 years ago

Immunome to Present at 2024 Bank of America Healthcare Conference

May 2, 2024, 8:00 AM EDT - 2 years ago

Immunome Appoints Kinney Horn as Chief Business Officer

Apr 25, 2024, 8:26 AM EDT - 2 years ago

Immunome Appoints Sandra M. Swain to Board of Directors

Apr 5, 2024, 8:00 AM EDT - 2 years ago

Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting

Apr 2, 2024, 2:07 PM EDT - 2 years ago

Immunome: An Oncology Powerhouse In The Making

Mar 28, 2024, 4:02 PM EDT - 2 years ago

Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets

EingeLTrade Apr. 1 at 8:29 PM

Up from here❔🤔 $IMNM

0 · Reply

TrendEdgeLogan Mar. 31 at 5:21 PM

$GH $KYMR $IMNM $NAMS $SOPH OCS PVLA ZYM SRZN ^^ best of the best healthcare / biotech names right now

0 · Reply

TradeMechanics_ Mar. 31 at 2:24 PM

0 · Reply

CEOBuysDisclosures Mar. 31 at 1:15 PM

$IMNM CEO purchased 25,450 shares at $19.67 for a total of $500,602. SIEGALL CLAY B now owns 690,704 shares. https://ceo-buys.com

0 · Reply

FilingTracker Mar. 31 at 11:13 AM

$IMNM $500K insider purchase by President and CEO: https://www.sec.gov/Archives/edgar/data/1167496/000116749626000003/xslF345X06/form4-03312026_110335.xml

0 · Reply

RadioIsotope25 Mar. 28 at 1:42 PM

3 · Reply

RadioIsotope25 Mar. 23 at 11:08 PM

$RADX Meets 90% news just broke on RAD101 $IMNM $AKTS

0 · Reply

Jeff9905 Mar. 19 at 5:41 PM

$IMNM so they have tripled their employee count in the last 18 months. Why can't they get anything to the finish line?

0 · Reply

RadioIsotope25 Mar. 15 at 3:23 PM

Radiopharmaceutical buyouts and Market Caps $RADX $IMNM $PYXS $CELC

1 · Reply

RadioIsotope25 Mar. 13 at 4:43 PM

Diamond in the Rough $RADX $PYXS $IMNM $SMMT $AKTS

0 · Reply

EingeLTrade Mar. 10 at 1:56 PM

Added more $IMNM

0 · Reply

RadioIsotope25 Mar. 6 at 12:18 AM

$30 target @ Jones Trading for Radiopharm Theranostics. $IMNM $PYXS $SLS $IOVA $RADX

3 · Reply

OfficialStocktwitsUser Mar. 4 at 2:57 PM

$IMNM RSI: 41.24, MACD: -0.3808 Vol: 1.37, MA20: 22.85, MA50: 22.76 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

d_risk Mar. 3 at 9:27 PM

$IMNM - Immunome Inc - 10K - Updated Risk Factors IMNM’s 2026 10-K sharpens early-stage and financing risk (no NDA/BLA, no near-term revenue, capital-intensive R&D) while adding program-specific IM‑3050 uncertainty, heavier dependence on ADC platform and in-licensed IP, broader global/regulatory and orphan/companion diagnostic hurdles, deeper patent and trademark vulnerability, expanded misconduct and anti-takeover concerns, and new litigation and Nasdaq compliance risks, even as some prior funding, foreign market, and analyst-coverage risks are pared back or reframed. #PharmaceuticalCommercialization #CompetitiveRisk #SupplyChainRisk #RegulatoryUncertainty #Biotechnology #EarlyStageRisk #CapitalIntensiveR&D #RegulatoryChallenges #IntellectualPropertyRisk 🟢 Added 🟠 Removed https://d-risk.ai/IMNM/10-K/2026-03-03

0 · Reply

d_risk Mar. 3 at 9:21 PM

0 · Reply

RadioIsotope25 Feb. 28 at 4:39 PM

$RADX Terbium and Lutetium $AKTS $CATX $IMNM https://youtu.be/AOalQM8zfDM

0 · Reply

BillionerOfKing Feb. 25 at 12:41 AM

$IMNM Current Stock Price: $22.11 Contracts to trade: $22.0 IMNM Mar 20 2026 Call Entry: $0.65 Exit: $0.91 ROI: 39% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

RadioIsotope25 Feb. 24 at 5:32 PM

AtomVie Global Radiopharma Supplies First Patient Dose in Radiopharm Theranostics' Phase 1/2a Clinical Study of 177Lu-BetaBart (RV-01) $RADX $CATX $LNTH $IMNM https://www.prnewswire.co.uk/news-releases/atomvie-global-radiopharma-supplies-first-patient-dose-in-radiopharm-theranostics-phase-12a-clinical-study-of-177lu-betabart-rv-01-302695311.html

0 · Reply

ManifestVision Feb. 20 at 12:57 PM

$IMNM Immunome develops antibody-based cancer therapies. Clinical data drives valuation. Development timelines are long.

0 · Reply

RadioIsotope25 Feb. 17 at 6:08 PM

$RADX $AKTS $CATX $IMNM

0 · Reply

flam70 Feb. 12 at 12:54 PM

$IMNM wainwright initiates with a buy and a $40 price target

0 · Reply

Wagner76 Feb. 11 at 4:40 PM

$IMNM What is going on today? Every time it appears this stock is going on a run, it goes in a fast retreat. Any news, or just another sell off?

1 · Reply

Market Cap	2.47B
Revenue (ttm)	6.94M
Net Income (ttm)	-212.39M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-3,060.37%
Debt to Equity Ratio	0.00

Volume	1,602,400
Avg Vol	1,379,606
Day's Range	N/A - N/A
Shares Out	113.13M
Stochastic %K	67%
Beta	2.13
Analysts	Strong Sell
Price Target	$35.54